• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1212045 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type; F' ?' C: E5 u  t
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 7 {3 ?8 f7 K  q0 y
+ Author Affiliations
2 a/ O& `4 b) U- o* q, @$ B# d: B# F3 y
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 3 _7 x6 S/ q# P2 V2 k! P. i: M
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
: c: g7 X  W4 }) T% P9 w5 M& D+ i3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan - P: D/ p5 X7 P! u, q
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 6 z' g3 U+ _, y3 ^: p' [
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
, g9 S/ Z0 _! ?4 K6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan # p3 P/ e* ?4 H- g
7Kinki University School of Medicine, Osaka 589-8511, Japan
1 D4 O# a( p4 O# ?4 N" T8Izumi Municipal Hospital, Osaka 594-0071, Japan * l/ {- o: H. T
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
& }& d- K6 s" I1 O7 {  jCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
7 k- s9 A# w3 ~  F* F7 o  h( t) AAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. ! g' B8 l! g' d( g  R; p2 _

$ n. z+ L9 n" n
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type ( l# |& Y- v! N; D0 \
# z; G# q* }& Q$ Y1 b
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
7 z' m: K' |+ U$ @+ M6 W/ w- u
% w# T' q# t3 g# }7 z& bAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  0 ]* f4 f; S" c9 @0 e/ |0 ^# e

2 O" z6 {5 S, U, w' d6 [; e+ P+ n+ V6 W* RPublished online on: Thursday, December 1, 2011
& |+ D7 F1 J$ {9 Y: t0 A
# z* ?! O8 v: E' `1 c- rDoi: 10.3892/ol.2011.507 / _+ Y, j9 a/ V3 v% P3 w' g% V8 D
/ c- U% E- h! A, c: E
Pages: 405-410 ! ?0 Z' Q: _$ e) U9 L
- W% [+ w5 ~" F
Abstract:
+ Y* f0 [$ |* K9 T! rS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
" x5 g- `  W) t! L* t  A. @9 [
# I8 T, u. D# s: ~
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
6 ^3 G2 e* B, G- }( E% H9 q/ b5 z( {F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 ; V) ^4 Y! t. ~/ l+ V
+ Author Affiliations
' o) S6 W3 h2 Y- v1 o1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
$ L6 |& p, h( E3 u4 x7 z9 V, o2Department of Thoracic Surgery, Kyoto University, Kyoto
& m9 x! B) }& |5 W3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan $ j) R6 o. C7 H5 \, j/ q
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
, Q  h  p: W3 Y5 }  P0 s3 S( Y  kReceived September 3, 2010. # m- C% Y5 t8 c
Revision received November 11, 2010. 3 y- T7 B$ n5 ~. J3 A
Accepted November 17, 2010.
* K/ d9 V: Z/ \! EAbstract
1 C2 A7 x! E  J8 |! L- g2 v8 i6 EBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. $ A9 [) z; q7 q- w" R% B) O& x' b
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
3 x4 U) O, A& m. [9 H+ HResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. . k1 n. \( U0 c
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
: A8 S& {8 Y! m& i
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。/ }7 b/ p& f8 b1 e5 f4 l% c$ V2 B
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
/ @  ]6 a) q& ?7 }
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy' S) d3 T. A4 S& Z6 ?5 d$ O/ w3 @
http://clinicaltrials.gov/ct2/show/NCT015235871 K- _+ O* Q# t3 P7 E
9 }/ {7 n! e, j1 `6 K6 @5 e
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC" a/ ?  ^! B) H: M% `9 N, L, @" F6 ~, |
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
8 b( ~0 e$ T! N5 H: W
9 V: Z" T3 J- V4 C: ~从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
! ~  Z( s0 ?! _& v% ]. `9 \& M至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
! O( W% H& y9 {  }从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
. m4 S) Y1 L2 ?2 a1 |  }- i0 M5 Y至今为止,未出 ...

; f0 r# A7 n5 ^' A6 N) i没有副作用是第一追求,效果显著是第二追求。
; Y# k( f# [) _$ x0 K1 w1 {, {不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表